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Abstract 
Objectives: To compare unintended pregnancy rates at 12 months between women receiving 
structured contraceptive counseling plus usual contraceptive care, and women receiving 
structured contraceptive counseling, healthcare provider education, and cost support for long-
acting reversible contraceptive (LARC) methods. 
Study Design: Using a controlled time-trend study design, we first enrolled 502 women receiving 
structured contraceptive counseling in addition to usual care (“Enhanced Care”) and 
subsequently enrolled 506 women to receiving counseling plus healthcare provider education 
and cost support for LARC methods (“Complete CHOICE”) at three federally qualified health 
centers (FQHC). Cost support included funds to health centers for “on-the-shelf” LARC methods 
and no-cost LARC methods for uninsured women. Participants completed in-person baseline 
surveys and follow-up surveys by telephone at 3, 6, and 12 months. We used Kaplan-Meier 
survival function to estimate 12-month unintended pregnancy rates and Cox proportional hazards 
regression to compare unintended pregnancy rates between the two groups. We imputed 
pregnancy outcomes for women lost to follow-up (9%) prior to 12 months. 
Results: “Complete CHOICE” participants were less likely to report an unintended pregnancy at 
12 months compared to “Enhanced Care”; 5.3 vs. 9.8 pregnancies per 100 women-years 
(p=0.01). After adjusting for confounders (recruitment site, race, age, and federal poverty level), 
women in “Complete CHOICE” had a 40% lower risk of unintended pregnancy at 12 months 
(HRadj 0.60; 95%CI 0.37-0.99). 
Conclusions: Contraceptive provision that includes cost support and healthcare provider 
education in addition to patient counseling reduced unintended pregnancy at 12 months 
compared to counseling plus usual contraceptive care.  
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Implications: A program of contraceptive care that includes comprehensive counseling, 
healthcare provider education, cost support, and on-the-shelf, long-acting reversible 
contraception can reduce unintended pregnancy compared to contraceptive counseling in 
addition to usual health center care in the FQHC setting. 
 
Keywords: Contraceptive counseling; long-acting reversible contraception; intrauterine device; 
contraceptive implant; unintended pregnancy
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1. Introduction 
Unintended pregnancy remains a persistent public health problem in the United States, 
with 45% of the 6.1 million annual pregnancies being unplanned (1). Due to high rates of 
effectiveness, long-acting reversible contraceptive (LARC) methods, including intrauterine 
devices (IUDs) and implants, have been proposed as a strategy to reduce unintended pregnancy 
(2-5). Our group previously conducted a research study, the Contraceptive CHOICE Project 
(CHOICE), which provided women with their preferred reversible contraceptive method at no 
cost and followed them over 2-3 years. The CHOICE intervention included 1) structured, 
evidence-based counseling, which presented reversible contraceptive methods in order of 
effectiveness; 2) healthcare provider education about evidence-based guidelines for 
contraception including IUDs and implants; 3) removal of structural barriers including patient 
cost; and 4) facilitation of same-day contraceptive initiation by maintaining in-clinic inventory of 
contraceptive methods including IUDs and implants. LARC uptake was high, with 75% of the 
participants choosing an IUD or implant (6). LARC users also had lower rates of unintended 
pregnancy compared to users of shorter-acting reversible methods (6-8).  
The CHOICE model proved successful in a research setting, where the majority of 
participants (70%) were recruited at the university-based research clinic and contraceptive 
counseling was provided by a trained research assistant at all recruitment sites. However, the 
success of the model in real-world clinical settings is unknown. Our primary objective was to 
implement two contraceptive programs adapted from the CHOICE Project in community health 
centers and compare subsequent rates of unintended pregnancy at 12 months between women 
receiving these models of care. We hypothesized that a program, which included structured 
contraceptive counseling plus healthcare provider education and funds to purchase LARC 
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methods, would have a greater reduction in unintended pregnancy by 12 months compared to a 
program which included only structured contraceptive counseling in addition to usual 
contraceptive care.  
2. Materials and Methods 
2.1 Study Design and Interventions 
We conducted a controlled time-trend design to compare two different models of 
contraceptive provision at three urban federally-qualified health centers (FQHCs) located in two 
Midwest cities. Controlled time-trend analysis is a nonrandomized study design where outcomes 
are compared before and after a change occurs in the healthcare setting (9). In the first study 
group, “Enhanced Care,” women received structured contraceptive counseling adapted from the 
CHOICE Project (10) in addition to the usual contraceptive care provided by the health center. 
Counseling was provided by existing health center staff members trained by our study team. The 
counseling used an evidence-based script which presented reversible contraceptive methods in 
order of effectiveness highlighting method duration and side effects. The mean length of 
counseling sessions in the study was 9.0 minutes (SD 3.6). For the second study group, 
“Complete CHOICE,” the program added healthcare provider contraceptive training and cost 
support for LARC methods to the same counseling. Cost support included upfront funds for 
health centers to purchase an in-clinic LARC inventory to provide no-cost LARC methods for 
uninsured patients and to ensure availability for same-day placement for all women regardless of 
insurance status. All three health centers already provided refillable methods of contraception 
such as oral contraceptive pills (OCPs) and depo-medroxyprogesterone acetate (DMPA), cost 
was based on a sliding fee scale. “Enhanced Care” was implemented first at all sites and a cohort 
of women were enrolled. The additional components of “Complete CHOICE” were then 
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subsequently implemented at all sites and a second cohort of women enrolled. The additional 
components represented the “change in the system” for the controlled time-trend design. Figure 1 
shows the study design and timeline. 
2.2 Participants 
Eligible women were 14-45 years, English or Spanish speaking, not currently pregnant, 
sexually active with a male partner or planning to become sexually active in the next 3 months, 
did not desire pregnancy in the next 12 months, at risk for unintended pregnancy (i.e. had not 
undergone sterilization or hysterectomy), and had an appointment at a participating health center. 
Women with one male sexual partner who had undergone vasectomy were ineligible. Current 
LARC users were only eligible to participate if they were seeking removal of their method at 
their healthcare appointment. Women did not have to choose a method of contraception to be 
eligible to participate. Site counselors primarily recruited patients scheduled for a gynecologic or 
family planning visit. However, any reproductive-age woman interested in contraception was 
eligible regardless of appointment type as long as they met the above inclusion criteria. 
Participants received a $20 gift card at baseline and a $10 gift card for each follow-up survey, up 
to $50 total for their participation. We obtained approval from the Human Research Protection 
Office at the Washington University in St. Louis School of Medicine prior to participant 
recruitment. Parental consent was not required for participants under 18 years of age, as it is not 
required for adolescents to access confidential reproductive health services. We registered the 
study with ClinicalTrials.gov (NCT02364037). 
2.3 Measures 
All women completed an interviewer-administered baseline questionnaire and follow-up 
surveys by telephone at 3, 6, and 12 months. If a woman reported a new pregnancy at any time 
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point during the 12 months, she was asked “At the time (you became pregnant), would you say 
you were trying to get pregnant?” Participants who responded “no” were coded as having an 
unintended pregnancy for the primary outcome. A member of the study team also administered 
the London Measure of Unplanned Pregnancy (11), a 6-item validated measure of pregnancy 
planning and intention, to all women who reported a pregnancy to assess pregnancy intention. 
The London Measure of Unplanned Pregnancy scores range from 0-12 and can categorize 
pregnancies as unplanned (0-3), ambivalent (4-9), or planned (10-12). When dichotomizing 
scores into planned and unplanned, unplanned and ambivalent are grouped together (11).  
2.4 Sample Size 
We assumed a 13% baseline annual unintended pregnancy rate for the FQHC population 
based on the national rate of 137 per 1,000 reproductive-age women with household incomes 
less than 100% of the federal poverty level (FPL) (12). We anticipated a small reduction in the 
unintended pregnancy rate for “Enhanced Care,” from 13% to 11%, due to the structured 
contraceptive counseling. Based on results from CHOICE, we anticipated a reduction in 
unintended pregnancy from 11% in “Enhanced Care” to 5% in “Complete CHOICE.”(6, 13) To 
account for possible clustering by health center, we performed a test of differences in proportions 
using a range of possible values. We increased the sample size by an additional 10% to 
compensate for lack of randomization and to be more conservative in our estimate. Using an 
alpha of 0.05, 80% power, and assuming 10% loss to follow-up, we needed 480 women in each 
group. We estimated a 10% loss to follow-up based on our retention rates in prior studies. We 
used REDCap electronic data capture tools for data collection and management (14). We 
performed data analysis using Stata 15 (StataCorp, College Station, TX).  
2.5 Statistical Analyses 
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For the outcome of unintended pregnancy at 12 months, participants contributed follow-
up time for the 12-month study period unless we censored them for the following: 1) 
discontinued method to seek pregnancy, 2) had an intended pregnancy, 3) had an unintended 
pregnancy, or 4) were lost to follow-up. Women with an intended pregnancy who did not report 
stopping contraception to conceive were censored at the estimated date of conception based on 
last menstrual period or estimated due date depending on reported data. Women with an 
unintended pregnancy were censored at the estimated date of conception. 
There were 11 women who crossed over from the “Enhanced Care” to “Complete 
CHOICE” group, as they presented for subsequent care during “Complete CHOICE” enrollment. 
Following intention-to-treat principles, we analyzed outcomes for these participants in the 
“Enhanced Care” group only. Due to missing pregnancy outcomes for the 92 participants lost to 
follow-up, we performed multiple imputation to impute unintended pregnancy outcomes and 
follow-up time (15). The multiple imputation model included age, race, ethnicity, FPL, desired 
contraceptive method, health center site, and study group as predictors for unintended pregnancy. 
Women lost to follow-up differed from women with complete follow-up by site, insurance 
status, FPL, and desired method. We created 10 datasets with imputed values that were then 
pooled. The aggregate multiple imputation dataset contributed an additional 12 unintended 
pregnancies (7 in “Enhanced Care” and 5 in “Complete CHOICE”). 
We estimated unintended pregnancy rates at 12 months using the Kaplan-Meier survival 
function and used the log rank test to examine differences between study groups. We performed 
univariate and multivariable Cox proportional hazards regressions to investigate associations 
between group assignment, baseline characteristics, and unintended pregnancy. We planned, a 
priori, to include age, race, Hispanic ethnicity, and FPL in the multivariable model as these 
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characteristics have previously been associated with unintended pregnancy (1). We also planned 
to include site due to baseline differences between health centers. Due to the limited number of 
pregnancy outcomes, we collapsed categorical variables into binary variables to reduce the 
number of covariates. We included age as a continuous variable. We investigated the presence of 
confounding by performing bivariate analyses adding baseline characteristics (i.e. age, race, 
ethnicity, parity) to study group indicator in the Cox regression model. Confounding was defined 
as a greater than 10% change in the association between study group and unintended pregnancy 
with or without the covariate of interest in the model. Model checking showed that Hispanic 
ethnicity failed the proportional hazards assumption. Therefore, we excluded ethnicity from the 
final multivariable model. We ran the univariate and multivariable models with and without 
imputed pregnancies included to assess for differences in effect size and significance. We 
calculated London Measure of Unplanned Pregnancy scores as previously described – scoring 
data were only available for participants with observed pregnancies (11). 
3. Results 
From June 2014 through September 2015, we enrolled 502 women into “Enhanced Care” 
and 506 women into “Complete CHOICE.” Baseline results have previously been described (16). 
Approximately 90% of eligible participants in each group completed follow-up surveys at 3, 6, 
and 12 months. Figure 2 shows the flow of study follow-up. The overall loss to follow-up at 12 
months was 9% for “Enhanced Care” and 10% for “Complete CHOICE.” Women lost to follow-
up were more likely to be uninsured (p<0.01), report a household income less than 100% FPL 
(p<.0.01), and more likely to receive OCPs, contraceptive patch, vaginal ring, or no method for 
their contraceptive method (p=0.02).  
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Women in “Complete CHOICE” were older, more likely to be Hispanic and uninsured, 
and less likely to be black, single, or report a history of unintended pregnancy (Table 1) 
compared to “Enhanced Care.” Women in “Complete CHOICE” had a lower risk of unintended 
pregnancy at 12 months, 5.3 compared to 9.8 per 100 reproductive-age women-years (Table 2, 
p=0.01). Figure 3 shows the Kaplan-Meier curve for the probability of unintended pregnancy 
over the 12-month time period by group (p=0.01). Due to the higher uptake of LARC methods in 
“Complete CHOICE,” we also assessed the risk of unintended pregnancy by contraceptive 
method received at enrollment visit. Women who received a LARC method were less likely to 
have an unintended pregnancy over 12 months (Figure 4, p<0.01).   
In the univariate Cox proportional hazards model, study group, site, age, race, and FPL 
were all significantly associated with risk of unintended pregnancy; women in “Complete 
CHOICE” and women enrolled at Health Centers B or C had a decreased risk and non-white and 
low-income women had an increased risk of unintended pregnancy (Table 3). We did not find 
evidence of confounding when education, marital status, insurance status, parity, and future 
pregnancy plans were added to the model with study group. Therefore, we included study group, 
site, age, race, and FPL in our final model. In the multivariable model, women in “Complete 
CHOICE” had a 40% reduction in the risk of unintended pregnancy (HRadj 0.60, 95%CI 0.37-
0.99). Women enrolled at Health Center B also had a decreased risk of unintended pregnancy. 
Low-income women had an increased risk of unintended pregnancy. Non-white race no longer 
remained significantly associated with unintended pregnancy in our adjusted model. 
We calculated London Measure of Unplanned Pregnancy scores for the 54 women who 
reported an unintended pregnancy and completed the survey (missing data n=5). All women had 
a London Measure of Unplanned Pregnancy score less than 10, which is consistent with either an 
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unplanned pregnancy or a pregnancy about which the woman was ambivalent; 46.3% with score 
0-3 (unplanned), 53.7% with score 4-9 (ambivalent). 
Due to the 11 participants who crossed over from “Enhanced Care” to “Complete 
CHOICE”, we repeated the analysis excluding these participants from “Enhanced Care.” This 
exclusion did not alter the effect size or statistical significance of our findings regarding 
unintended pregnancy rates or the Cox proportional hazards model. The unintended pregnancy 
rates excluding these participants were 10.1 in “Enhanced Care” vs. 5.3 per 100 reproductive-age 
women-years in “Complete CHOICE” (p=0.01). We also performed analyses for the outcome of 
unintended pregnancy with and without the imputed values. The unintended pregnancy rates 
excluding imputed values were 8.4 in “Enhanced Care” vs. 4.2 per 100 reproductive-age women-
years in “Complete CHOICE” (p=0.01). In the multivariable Cox proportional hazards 
regression, the adjusted hazard ratio for unintended pregnancy without imputed values was 
similar to hazards ratio with imputed values at HRadj 0.58 (95%CI 0.34-0.99).  
4. Discussion 
The results from our study show that the CHOICE program of contraceptive care can 
reduce unintended pregnancy when implemented in an FQHC setting. Women enrolled in 
“Complete CHOICE” were 40% less likely to have an unintended pregnancy at 12 months 
compared to women in “Enhanced Care.” The proportion of women with an unintended 
pregnancy was 9.2% in “Enhanced Care” which was slightly lower than the 11% initially 
assumed for our sample size calculation. The proportion of women with an unintended 
pregnancy in “Complete CHOICE” was 4.9% and similar to the anticipated 5%. Using time-to-
event analysis, we found a statistically significant reduction in the rate of unintended pregnancy 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
between the two groups. Even after adjustment for possible confounders, women in “Complete 
CHOICE” were less likely to have an unintended pregnancy by 12 months. 
In this study, we implemented and compared our interventions among a population of 
predominantly low-income women seeking medical care at FQHCs. Even after adjusting for the 
study group, age, race, and site, low-income women (at or below the federal poverty level) had 
more than a two-fold increase in the risk of unintended pregnancy (HRadj 2.16, 95%CI 1.03-
4.52). Future research is necessary to improve our understanding of the risk of unintended 
pregnancy among low-income women, even when access is improved and cost removed as a 
barrier. One possibility is that different concepts of pregnancy planning among low-income 
women (17-19) may affect how women report pregnancy intention. Some studies have shown an 
association between black race and unintended pregnancy (20, 21). However, a recent study 
found no link between race and unintended pregnancy (22). In our study after adjusting for study 
group, enrollment site, age, and FPL, non-white race was no longer significantly associated with 
unintended pregnancy. In prior studies, where an association between race and unintended 
pregnancy was observed, race may have served as a marker for socioeconomic status or access to 
care.  
There are several limitations to our study. The lack of a randomized controlled trial 
design did not allow us to control for possible unmeasured confounding between the groups. We 
did perform a multivariable analysis to control for these baseline differences. However, these 
differences may reflect a lower risk of unintended pregnancy among “Complete CHOICE” 
participants compared to “Enhanced Care”.  
We also had participants lost to follow-up over the study period. While our loss to 
follow-up was similar to anticipated (9%), this loss does mean that we may have missed some 
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pregnancies that occurred during study participation, which would have underestimated our 
unintended pregnancy rate. The loss to follow-up was similar between the two groups (9% vs. 
10%) making it less likely that missed pregnancies would have altered the difference observed 
between the groups. In order to account for possible unobserved pregnancies, we performed 
multiple imputation to impute unintended pregnancy outcomes for participants lost to follow-up. 
We found similar effect sizes in our survival analysis with and without the imputed pregnancies.  
Our objective was to compare two programs of contraceptive care adapted from the 
CHOICE Project. We found that implementation of “Complete CHOICE”—with structured 
contraceptive counseling, healthcare provider education, and structural changes to reduce 
barriers to LARC—reduced the risk of unintended pregnancy compared to “Enhanced Care.” 
Improved access to LARC methods and the subsequent reduction in unintended pregnancies 
should encourage other FQHCs to consider implementing programs that reduce barriers to 
contraception. While contraceptive counseling is a key component of family planning care, our 
results demonstrate that interventions must also address other barriers, including provider 
practice and cost, to truly increase contraceptive access for patients.
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Figure 1: Study design and timeline. 
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Figure 2: Participant flow of study follow-up through 12 months 
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Table 1: Baseline demographic and reproductive characteristics of participants stratified 
by study group. 
Characteristic 
Enhanced Care 
(n=502) 
N(%) 
Complete 
CHOICE 
(n=506)  
N(%) 
P 
 Value
 *
 
Age   <0.01 
14-19 years 88 (17.5) 92 (18.2)  
20-29 years 287 (57.2) 244 (48.2)  
30-45 years 127 (25.3) 170 (33.6)  
Race   <0.01 
Black 374 (74.5) 320 (63.2)  
White 96 (19.1) 159 (31.4)  
Other 32 (6.4) 27 (5.3)  
Hispanic   0.02 
Yes 39 (7.8) 66 (13.0)  
Missing 3 (0.6) 1 (0.2)  
Education   0.08 
≤ High school 317 (63.2) 345 (68.2)  
Some college 153 (30.5) 123 (24.3)  
4+ years college 32 (6.4) 38 (7.5)  
Marital status    <0.01 
Never married 394 (78.5) 341 (67.4)  
Married/living with partner 85 (16.9) 132 (26.1)  
Separated/divorced/widowed 23 (4.6) 33 (6.5)  
Insurance status   0.09 
None 120 (23.9) 149 (29.5)  
Public 311 (62.0) 274 (54.2)  
Commercial 70 (13.9) 82 (16.2)  
Missing 1 (0.2) 1 (0.2)  
Federal poverty level   0.57 
≤ 100% 382 (76.1) 384 (75.9)  
101%-200% 102 (20.3) 95 (18.8)  
≥ 201% 16 (3.2) 24 (4.7)  
Missing 2 (0.4) 3 (0.6)  
Parity   0.14 
0 161 (32.1) 165 (32.6)  
1-2 245 (48.8) 221 (43.7)  
3+ 96 (19.1) 120 (23.7)  
History of a prior unintended 
pregnancy 
  0.06 
Yes 257 (51.2) 222 (43.9)  
Missing 1 (0.2) 2 (0.4)  
Feeling if got pregnant in the next   0.03 
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12 months 
Upset 322 (64.1) 293 (57.9)  
Neutral 102 (20.3) 101 (20.0)  
Pleased 49 (9.8) 60 (11.9)  
Unsure 29 (5.8) 52 (10.3)  
Contraceptive method at end of 
baseline visit 
  <0.01 
Hormonal IUD 10 (2.0) 40 (7.9)  
Copper IUD 2 (0.4) 11 (2.2)  
Implant 17 (3.4) 110 (21.7)  
DMPA 220 (43.8) 145 (28.7)  
OCP/patch/ring 113 (22.5) 66 (13.0)  
Condoms 35 (7.0) 57 (11.3)  
Other 13 (2.6) 8 (1.6)  
Nothing 92 (18.3) 69 (13.6)  
*2 used to estimate p values 
IUD – intrauterine device; DMPA – depot medroxyprogesterone acetate; OCP – oral 
contraceptive pills  
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Table 2: Unintended pregnancy outcomes at 12 months for “Enhanced Care” and “Complete CHOICE” 
groups.  
 
Enhanced Care 
(N = 502) 
Complete 
CHOICE 
(N = 506) 
P  
Value 
Number of intended pregnancies, n 3 4  
Number of unintended pregnancies, n 46 25  
Person-time (years) 464.02 466.73  
Proportion with an unintended pregnancy, 
% 
9.2 4.9 0.01
†
 
Rate of unintended pregnancy per 100 
women-years (95% CI)
‡
 
9.8 
(7.4-13.0) 
5.3 
(3.6-7.7) 
0.01 
† P value calculated using X2 test 
‡ 
Rates of unintended pregnancy calculated using Kaplan-Meier survival function; p value calculated 
using log rank test.  
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Figure 3: Kaplan Meier curve comparing the probability of unintended pregnancy over 12 
months for “Enhanced Care” and “Complete CHOICE” groups. 
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Figure 4: Kaplan-Meier curve comparing the probability of unintended pregnancy over 12 
months for women who received a LARC method compared to a non-LARC method at their 
enrollment visit 
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Table 3: Univariate and multivariable Cox proportional hazard regression model for baseline 
characteristics, group, and site and outcome of unintended pregnancy 
 Univariate Analysis Multivariable Analysis† 
Baseline Characteristic HR (95% CI) HR (95% CI) 
Group   
Enhanced Care Ref. Ref. 
Complete CHOICE  0.54 (0.32-0.88) 0.60 (0.37-0.99) 
Enrollment site   
Health Center A Ref. Ref. 
Health Center B 0.21 (0.09-0.47) 0.21 (0.08-0.57) 
Health Center C 0.56 (0.33-0.93) 0.62 (0.36-1.05) 
Age (continuous)  0.58 (0.35-0.94) 0.94 (0.91-0.98) 
Hispanic 0.85 (0.37-1.96) --- 
Race   
White Ref. Ref. 
Non-White 2.42 (1.20-4.86) 0.77 (0.32-1.83) 
Federal poverty level   
≤ 100% 2.55 (1.22-5.32) 2.16 (1.03-4.52) 
≥ 101% Ref. Ref. 
† Multivariable model adjusted for site, race, age, and federal poverty level. 
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